(131 days)
Hairmax Lasercomb
MEP-90
No
The device description and performance studies focus on the light therapy mechanism and its effectiveness, with no mention of AI or ML capabilities. The automatic pause feature is a simple sensor-based function, not indicative of AI/ML.
Yes
The "Intended Use / Indications for Use" states that the device is "indicated to promote hair growth in males with androgenetic alopecia." Promoting hair growth to treat androgenetic alopecia is a therapeutic purpose.
No.
The device is used to promote hair growth by providing light therapy, not to diagnose a condition.
No
The device description clearly states it consists of physical components like lasers, LEDs, a helmet, and a liner, indicating it is a hardware device with integrated software for control and operation.
No, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- IVD Definition: In Vitro Diagnostic devices are used to examine specimens taken from the human body (like blood, urine, tissue) to provide information for diagnosis, monitoring, or screening.
- Device Function: The igrow-II Hair Growth System is a therapeutic device that uses light energy to stimulate hair growth directly on the body. It does not analyze any biological samples.
- Intended Use: The intended use is to "promote hair growth in males with androgenetic alopecia," which is a therapeutic purpose, not a diagnostic one.
The device description, performance studies, and key metrics all relate to the device's ability to stimulate hair growth on the scalp, not to analyze biological samples for diagnostic purposes.
N/A
Intended Use / Indications for Use
The igrow-II Hair Growth System is indicated to promote hair growth in males with androgenetic alopecia who have Norwood Hamilton Classifications of IIa to V and Fitzpatrick Skin Phototypes I to IV.
Product codes
OAP
Device Description
The Igrow-II Hair Growth System consists of 21 red visible light, diode lasers and 30 red light super-luminescent diodes configured within an outer helmet and protective inner liner. The use of diode lasers and non-laser LEDs provides for a full coverage of the upper 1/3 of the head; i.e., the area commonly covered with stylized hair. The helmet system will automatically pause therapy if the subject's head is moved outside of the zone of radiation and will resume therapy when the correct head position is re-established. At the end of the therapy cycle, the system signals that therapy is complete and ready to be powered down. by emitting an audible beep pattern.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
upper 1/3 of the head
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies
A multi-center, randomized, double blinded, placebo controlled, prospective trial was conducted at two sites in the United States. Subjects received either the igrow-II Hair Growth System, unlabeled with any markings or an equivalent, red light, incandescent light system. Identical, helmet housings were used for both light sources to further mask the actual test device from the placebo device. Adequate data, from prior testing, was already available to the sponsor, validating the efficacy of the igrow-II Hair Growth System , obviating the need to test lasers versus LEDs, which the sponsor and the FDA consider equal in their tissue interaction profile. All subjects self-administered treatments, at home, for 16 weeks, with either the actual test device or the placebo device. Treatments were administered every other day, for 20 minutes. Subjects treated in the actual test laser group demonstrated a 100 % effectiveness; that is, all of the subjects showed a positive result for an increase in terminal hair counts. In the placebo group, there was some increment over baseline and some demonstrated a decrease over baseline. Overall, the active group demonstrated a 39% positive variance over the placebo group from baseline.
Key Metrics
Effectiveness (positive result for an increase in terminal hair counts) for active group: 100%
Positive variance of active group over placebo group from baseline: 39%
Predicate Device(s)
Hairmax Lasercomb
Reference Device(s)
MEP-90
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 890.5500 Infrared lamp.
(a)
Identification. An infrared lamp is a device intended for medical purposes that emits energy at infrared frequencies (approximately 700 nanometers to 50,000 nanometers) to provide topical heating.(b)
Classification. Class II (special controls). The device, when it is an infrared therapeutic heating lamp, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 890.9.
0
122248
510(k) Summary
Apira Science, Inc.
DEC 0 5 2012
Submitter's Contact Information
Name:
· Raymond R. Blanche
Address
NST Consulting, LLC 641 Shunpike Road, Suite 311 Chatham, NJ 07928
Telephone: Facsimile:
(973-539-7444 (973) 539-7445
Name of Device and Name/Address of Sponsor
Trade Name:
igrow-II Hair Growth System
Sponsor Contact Information:
Morgan Pepitone Apira Science, Inc. 2601 Main Street, Suite 530 Irvine, CA 92614
| Common or Usual Name: | Lamp, non-heating, for promotion of hair growth |
|---|---|
| Classification Name: | Infrared lamp per 21 CFR 890.5500 |
| Classification Code: | OAP ( Laser, comb, hair) |
Predicate Devices:
Device Trade Name
Manufacturer
Hairmax Lasercomb
·Lexington International, LLC
Reference Devices:
MEP-90
Midwest RF
Date Prepared:
July 20, 2012 November 13, 2012 Revised
1
K122248/ 2/4
Intended Use / Indications for Use
The igrow-II Hair Growth System is indicated to promote hair growth in males with androgenetic alopecia who have Norwood Hamilton Classifications of IIa to V and Fitzpatrick Skin Phototypes I to IV.
Technological Characteristics
The Igrow-II Hair Growth System consists of 21 red visible light, diode lasers and 30 red light super-luminescent diodes configured within an outer helmet and protective inner liner. The use of diode lasers and non-laser LEDs provides for a full coverage of the upper 1/3 of the head; i.e., the area commonly covered with stylized hair. The helmet system will automatically pause therapy if the subject's head is moved outside of the zone of radiation and will resume therapy when the correct head position is re-established. At the end of the therapy cycle, the system signals that therapy is complete and ready to be powered down. by emitting an audible beep pattern.
Performance Data:
A multi-center, randomized, double blinded, placebo controlled, prospective trial was conducted at two sites in the United States. Subjects received either the igrow-II Hair Growth System, unlabeled with any markings or an equivalent, red light, incandescent light system. Identical, helmet housings were used for both light sources to further mask the actual test device from the placebo device. Adequate data, from prior testing, was already available to the sponsor, validating the efficacy of the igrow-II Hair Growth System , obviating the need to test lasers versus LEDs, which the sponsor and the FDA consider equal in their tissue interaction profile. All subjects self-administered treatments, at home, for 16 weeks, with either the actual test device or the placebo device. Treatments were administered every other day, for 20 minutes. Subjects treated in the actual test laser group demonstrated a 100 % effectiveness; that is, all of the subjects showed a positive result for an increase in terminal hair counts. In the placebo group, there was some increment over baseline and some demonstrated a decrease over baseline. Overall, the active group demonstrated a 39% positive variance over the placebo group from baseline. Most significant was the actual test group's decrease in terminal hair counts which was zero compared to the placebo group which was highly significant. This points strongly to the hypothesis that red laser and LED light's characteristics for delivering precise,
2
122248 3/4
controlled, consistent irradiance is essential in effecting a reproducible therapeutic outcome . There were no anticipated adverse events and none were reported from either therapy administered that were study related. In all instances the igrow-II Hair Growth System functioned as anticipated and hair re-growth was observed to be significantly greater than that of the incandescent placebo system.
Substantial Equivalence
The igrow -II Hair Growth System is as safe and effective as the other device in its class, the Hairmax Lasercomb. This is a unique distinction for the sponsor of the igrow-II Hair Growth System because the Food and Drug Administration has created a new classification for this device, effective January 18, 2007. It is called OAP. There are no other devices listed within this classification, which the sponsor believes serves to narrow down the predicate device issue to one key comparison. Does the igrow-II Hair Growth System demonstrate substantial equivalence to the Hairmax Lasercomb for the indicated use and to the MEP for the specific design characteristic? The sponsor believes that with the exception of the configuration of the predicate device, the Hairmax Lasercomb, which is a hair comb configuration and the igrow-II Hair Growth System , is a helmet, the devices are identical in the key areas that effect safety and efficacy. The MEP -90 is offered as a reference proof of the functionality and acceptability of a helmet design, both technically and clinically.
Both systems, which use red light diode lasers and/or the equivalent, super-luminescent, light emitting diodes are classified as class IIIa/3R laser systems by the IEC standard for allowable emission levels, which is a recognized standard by the FDA as well, and the adverse event profile is the same. The sponsor believes that the difference in the physical appearance or in the method of delivering the radiant energy of the two systems is of no consequence and does not effect the therapeutic value or the safety profile. The sponsor believes that difference between a hand-held laser system (the Hairmax Lasercomb) and one that is a hands-free helmet design (the igrow-II Hair Growth System ) does not create a performance difference, but rather a physical appearance difference only. This design difference is mitigated by the marketing clearance issued to the MEP90, which is also a helmet design , demonstrating that a hair comb style device is not a performance requirement for efficacy. Finally, the clinical data summarized in the 510(k) notice confirms the safety and efficacy of the igrow-II Hair Growth System for OTC Use, according to Part 21 CFR 801 Subpart C). For these reasons, the igrow-II Hair Growth System satisfies the FDA 's substantial equivalence with respect to intended use, technological and design characteristics.
With the relatively new classification of OAP, the sponsor respectfully proposes that the FDA has acknowledged that Low-Level Laser/Light Therapy is a viable modality for treating androgenetic alopecia in the specified patient group and that the red light lasers in class IIIa/3R. used in the igrow-II Hair Growth System, are substantially equivalent to the Hairmax Lasercomb .
3
K 122248 4/4
The clinical data presented by the sponsor for the igrow-II Hair Growth System further validates that red light lasers are effective in promoting hair growth and does not present any safety issues. Therefore, the igrow-II Hair Growth System satisfied the FDA's substantial equivalence criteria. Thus, the FDA should clear the device via the 510(k) notice containing clinical data.
4
DEPARTMENT OF HEALTH & HUMAN SERVICES
Image /page/4/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized eagle with three tail feathers, representing the department's mission to protect the health of all Americans and provide essential human services. The logo is surrounded by the text "DEPARTMENT OF HEALTH & HUMAN SERVICES • USA" in a circular arrangement.
Public Health Service
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-002
IGrow II Hair Growth System % NST Consulting, LLC Mr. Raymond R. Blanche 641 Shunpike Road, Suite 311 Chatham. New Jersey 07928
December 5, 2012
Re: K122248
Trade/Device Name: igrow-II Hair Growth System Regulation Number: 21 CFR 890.5500 Regulation Name: Lamp, Non-Heating for Hair Growth Regulatory Class: Class II Product Code: OAP Dated: November 16, 2012 Received: December 03, 2012
Dear Mr. Blanche:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
5
Page 2 - Mr. Raymond R. Blanche
Enclosure
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please 11 you desire specific advice 10. your as meets offices/CDRH/CDRHOffices/ucm115809.htm for go to mtp.//www.luagemal Health's (CDRH's) Office of Compliance. Also, please the Center for Devices and Radionanding by reference to premarket notification" (21CFR Part note the regulation entired, "Misoranants of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Tou may obtain other general miormational and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely yours.
Peter D. Rumm -S
Mark N. Melkerson Acting Director Division of Surgical Devices Office of Device Evaluation Center for Devices and Radiological Health
6
'INDICATIONS FOR USE
510(k) Number: K 122248
Device Name: igrow-II Hair Growth System
Indications for Use:
The igrow-II Hair Growth System is indicated to promote hair growth in males with androgenetic alopecia who have Norwood Hamilton Classifications of Ila to V and Fitzpatrick Classification of Skin Phototypes I to IV.
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEED)
Concurrence of CDRH, Office of device Evaluation (ODE)
Prescription Use _ X (Part 21 CFR 801 Subpart D)
ੰ ਪ੍ਰ
OR
Over-the -Counter Use (Part 21 CFR 801 Subpart C)
Neil R Ogden 2012.12.03 14:33:36 -05'00' (Division Sign-off) for MXM Division of Surgical Devices 510(k) Number K122248
7
Premarket Notification for the igrow-II Hair Growth System, Revised 11/13/2012
and the comments of the comments of the comments of the comments of the comments of
:
:
.
:
.
the submit and the submit of the subscription of the sub-
.